Structural Fomula (Fesoterodine Fumarate Extended Release Tablets 1)
Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 65162-370
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 65162-370). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Fesoterodine Fumarate Extended Release Tablets 2)
The text describes a figure showing the change in the number of urinations per 24 hours in a study with three groups: a placebo group, a group taking fesoterodine fumarate 4mg, and a group taking fesoterodine fumarate 8mg. The figure tracks the change over a period of 12 weeks. The title of the figure is "Change in Number of Micturitions per 24 h (Study 1)". The description mentions "Mean change from baseline", but no values are provided.*
Figure 2 (Fesoterodine Fumarate Extended Release Tablets 3)
The text describes a graph that shows the change in urge incontinence episodes per 24 hours in a study which took place across 12 weeks. The graph displays three results: a placebo group of 211 individuals, a group of 199 individuals given Fesoterodine fumarate 4mg, and a group of 223 individuals given Fesoterodine fumarate 8mg. The text also provides a title for the graph and a measurement unit for the y-axis.*
Figure 3 (Fesoterodine Fumarate Extended Release Tablets 4)
This is a graph showing the mean change in the number of micturitions per 24 hours over a 12-week period for three groups: placebo (N=266), fesoterodine fumarate 4 mg (N=267), and fesoterodine fumarate 8 mg (N=267). The x-axis shows the weeks while the y-axis shows the change from baseline. No other information is available.*
Figure 4 (Fesoterodine Fumarate Extended Release Tablets 5)
The text describes a figure showing the change in urge incontinence episodes per 24 hours over a 12 week period in a study with three groups: a placebo group (N=205), a group taking fesoterodine fumarate 4 mg (N=228), and a group taking fesoterodine fumarate 8 mg (N=218). The x-axis shows the weeks and the y-axis shows the mean change from baseline in urge incontinence episodes per 24 hours.*
4 mg 30 Count Label (Fesoterodine Fumarate Extended Release Tablets 6)
This text describes a medication with the NDC code 65162-369-03, which comes in the form of an extended-release film-coated tablet containing 4mg of fesoterodine fumarate. The usual dosage and storage instructions are provided alongside a request for pharmacists to dispense the medication with a patient information leaflet and protect it from moisture. The medication is distributed by Amneal Pharmaceuticals LLC.*
8 mg 30 Count Label (Fesoterodine Fumarate Extended Release Tablets 7)
This is a medication with NDC number 65162-370-03. Each tablet of this medication is extended-release and film-coated containing 8mg of fesoterodine fumarate. The recommended dosage of this medication is available in the accompanying prescribing information. It is suggested to store the tablets at 20 to 25°C (68 to 77°F) with excursions permitted between 15 to 30°C (59 to 86°F). The medication should be protected from moisture. It is distributed by Amneal Pharmaceuticals LLC, located in Bridgewater, NJ. This information is current as of January 2021.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
